^
    24d
    NCI-2023-09969: Donor Immune Cells (TGFbi NK Cells) and Isatuximab for the Treatment of Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=3, Completed, Elvira Umyarova | Active, not recruiting --> Completed
    Trial completion
    |
    SLAMF7 (SLAM Family Member 7)
    |
    cyclophosphamide • Sarclisa (isatuximab-irfc) • Hemady (dexamethasone tablets) • UD TGFbetai NK cells
    25d
    DARANIVOVAX: Anti-CD38 Antibody With KRAS Vaccine and Anti-PD-1 Antibody in Subjects With Pancreatic Ductal Adenocarcinoma and Refractory Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=19, Active, not recruiting, Georgetown University | Recruiting --> Active, not recruiting | N=54 --> 19
    Enrollment closed • Enrollment change
    |
    KRAS (KRAS proto-oncogene GTPase) • STK11 (Serine/threonine kinase 11)
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Opdivo (nivolumab) • Darzalex Faspro (daratumumab and hyaluronidase-fihj)
    25d
    TRANSCEND LTE: A Study to Learn More About the Long-Term Safety and Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR) or Microvascular Inflammation (MVI) (TRANSCEND/TRANSPIRE LTE) (clinicaltrials.gov)
    P3, N=201, Enrolling by invitation, Biogen | N=120 --> 201
    Enrollment change
    |
    felzartamab (MOR202)
    29d
    AugMMent: GMMG-HD11/DSMM XXI/64007957MMY3010 (clinicaltrials.gov)
    P3, N=399, Not yet recruiting, University of Heidelberg Medical Center
    New P3 trial
    |
    lenalidomide • bortezomib • Darzalex (daratumumab) • melphalan • Tecvayli (teclistamab-cqyv)
    1m
    Escalation of Doses of Daratumumab in Combination With Chemotherapy (Idarubicin and Cytarabine or CPX-351) in Patients of 60 Years Old or More With Adverse Risk Acute Myeloblastic Leukemia (AML) (DARALAM) (clinicaltrials.gov)
    P1, N=12, Recruiting, Nantes University Hospital | Not yet recruiting --> Recruiting | Trial completion date: Jan 2028 --> Aug 2028 | Trial primary completion date: Jan 2028 --> Aug 2028
    Enrollment open • Trial completion date • Trial primary completion date • IO biomarker
    |
    Darzalex (daratumumab) • Vyxeos (cytarabine/daunorubicin liposomal formulation) • idarubicin hydrochloride
    1m
    GEM21menos65: NDMM Patients Candidates for ASCT Comparing Extended VRD Plus vs. Isa-VRD vs. Isa-V-Iberdomide (clinicaltrials.gov)
    P3, N=480, Recruiting, PETHEMA Foundation | Not yet recruiting --> Recruiting
    Enrollment open
    |
    lenalidomide • bortezomib • dexamethasone • Sarclisa (isatuximab-irfc) • iberdomide (CC-220)
    1m
    TRIlogy-7: A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Planned (clinicaltrials.gov)
    P3, N=1000, Not yet recruiting, Janssen Research & Development, LLC
    New P3 trial
    |
    lenalidomide • bortezomib • Darzalex (daratumumab) • ramantamig (JNJ-5322) • dexamethasone injection
    1m
    Daratumumab, Ixazomib, and Dexamethasone in AL Amyloidosis (clinicaltrials.gov)
    P1, N=21, Completed, M.D. Anderson Cancer Center | Active, not recruiting --> Completed | Trial completion date: May 2027 --> Jun 2026 | Trial primary completion date: May 2027 --> Jun 2026
    Trial completion • Trial completion date • Trial primary completion date
    |
    Ninlaro (ixazomib) • Darzalex (daratumumab) • dexamethasone injection
    1m
    AURIGA: A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant (clinicaltrials.gov)
    P3, N=200, Completed, Janssen Research & Development, LLC | Active, not recruiting --> Completed
    Trial completion • Minimal residual disease
    |
    lenalidomide • Darzalex Faspro (daratumumab and hyaluronidase-fihj)
    1m
    CHAMPION-01: Isatuximab-VRd in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Patients (clinicaltrials.gov)
    P=N/A, N=333, Recruiting, Shanghai Zhongshan Hospital
    New trial
    |
    lenalidomide • bortezomib • Sarclisa (isatuximab-irfc)
    1m
    CAREMM-011: CM336 Plus Isa-VR in Newly Diagnosed Primary Plasma Cell Leukemia (clinicaltrials.gov)
    P2, N=24, Not yet recruiting, Institute of Hematology & Blood Diseases Hospital, China
    New P2 trial
    |
    lenalidomide • bortezomib • Sarclisa (isatuximab-irfc)
    1m
    iFIT: Personalising Treatment for Myeloma Patients Based on Initial Response to NHS Treatment and Their Overall Fitness Level (clinicaltrials.gov)
    P3, N=1226, Not yet recruiting, University of Leeds
    New P3 trial
    |
    IFIT1 (Interferon Induced Protein With Tetratricopeptide Repeats 1) • IFIT2 (Interferon Induced Protein With Tetratricopeptide Repeats 2)
    |
    lenalidomide • dexamethasone • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • Talvey (talquetamab-tgvs) • Tecvayli (teclistamab-cqyv)